Health BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering August 7, 2026
Health Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq August 6, 2026
Health LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook August 6, 2026
Health UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada’s Drug Agency (CDA-AMC) for Acute Migraine Treatment August 4, 2026
Health Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma August 4, 2026
Search
Health
August 7, 2026
August 6, 2026
August 6, 2026
August 6, 2026
August 6, 2026
August 6, 2026
August 5, 2026
August 4, 2026
August 4, 2026
August 4, 2026
